Find an expert
Our panel of editors are available for interview
Professor Gisli Jenkins
Chair of the Editorial Board for BMJ Open Respiratory Research
Professor Gisli Jenkins is an NIHR Research Professor and holds the Margaret Turner-Warwick Chair of Thoracic Medicine at Imperial College London, Head of the Margaret Turner-Warwick Centre for Fibrosing Lung Diseases at the National Heart and Lung Institute. Prof Jenkins’ research focuses on Interstitial Lung Diseases, and Pulmonary Fibrosis in particular. He is the Principal Investigator of a number of longitudinal observational studies including the PROFILE study, the INJUSTIS Study, the UKILD Post COVID ILD study as well as the DEMISTIFI Multi-Morbidity consortium.
Dr Lucy Frith
Associate Editor of the Journal of Medical Ethics
Dr Lucy Frith is currently a reader in Bioethics and Social Science the Faculty of Health and Life Science at the University of Liverpool. Her research focuses on the social and ethical aspects of health-care decision-making, policy and regulation, with a particular interest in empirical ethics and socio-legal approaches.
Dr James Cave
Editor-in-Chief of the Drugs and Therapeutics Bulletin
Dr James Cave has been a GP for over 25 years. He currently works for Red Whale, providing courses for GP’s that take the latest research and demonstrate how it might be used in practice. James was awarded an OBE for services to medicine in 2009.
Richard Hurley
Features and Debates Editor – The BMJ
Richard Hurley is The BMJs features and debates editor, responsible for our head to head debates; features, and essays. He’s particularly interested in poverty, migration, doctor assisted dying and illicit drug policy and their impact on health.
Professor Ganesan Karthikeyan
Editor-in-Chief Open Heart
Professor Karthikeyan is a clinical, interventional cardiologist and a Senior International Fellow of the Population Health Research Institute at McMaster University in Canada, as well as Professor of Cardiology at AIIMS. His research is mainly focused on cardiovascular diseases affecting low and middle income countries, including valvular heart disease, particularly rheumatic heart disease (RHD), mechanical valve thrombosis, anticoagulation, and indigenous drug-eluting stents.
